tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ANTX Stock Latest News

AN2 Therapeutics Promotes Joshua Eizen to Key Roles
Company AnnouncementsAN2 Therapeutics Promotes Joshua Eizen to Key Roles
4d ago
8K
ANTX
AN2 Therapeutics gets continuation grant to discover novel boron based therapies
PremiumThe Fly
AN2 Therapeutics gets continuation grant to discover novel boron based therapies
24d ago
ANTX
AN2 Therapeutics adopts limited duration stockholder rights plan
PremiumThe Fly
AN2 Therapeutics adopts limited duration stockholder rights plan
3M ago
ANTX
AN2 Therapeutics reports Q2 EPS (48c), consensus (59c)
PremiumThe Fly
AN2 Therapeutics reports Q2 EPS (48c), consensus (59c)
3M ago
ANTX
Morning Movers: Iteris skyrockets following take-private agreement
PremiumThe Fly
Morning Movers: Iteris skyrockets following take-private agreement
3M ago
CGC
ITI
AN2 Therapeutics downgraded to Underperform from In Line at Evercore ISI
PremiumThe FlyAN2 Therapeutics downgraded to Underperform from In Line at Evercore ISI
3M ago
ANTX
AN2 Therapeutics to terminate Phase 2, Phase 3 parts of EBO-301 trial
Premium
The Fly
AN2 Therapeutics to terminate Phase 2, Phase 3 parts of EBO-301 trial
3M ago
ANTX
AN2 Therapeutics downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
AN2 Therapeutics downgraded to Market Perform from Outperform at Leerink
3M ago
ANTX
AN2 Therapeutics price target lowered to $3 from $6 at JMP Securities
PremiumThe Fly
AN2 Therapeutics price target lowered to $3 from $6 at JMP Securities
3M ago
ANTX
AN2 Therapeutics Announces Major Restructuring and Cost-Cutting Measures
PremiumCompany Announcements
AN2 Therapeutics Announces Major Restructuring and Cost-Cutting Measures
3M ago
8K
ANTX
Intuit initiated, Charter downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Intuit initiated, Charter downgraded: Wall Street’s top analyst calls
4M ago
PR
LPG
AN2 Therapeutics price target lowered to $2 from $7 at Evercore ISI
PremiumThe Fly
AN2 Therapeutics price target lowered to $2 from $7 at Evercore ISI
6M ago
ANTX
AN2 Therapeutics reports Q1 EPS (56c), consensus (62c)
PremiumThe FlyAN2 Therapeutics reports Q1 EPS (56c), consensus (62c)
6M ago
ANTX
AN2 Therapeutics upgraded to Outperform from Market Perform at JMP Securities
Premium
The Fly
AN2 Therapeutics upgraded to Outperform from Market Perform at JMP Securities
7M ago
ANTX
AN2 Therapeutics’ High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties
Premium
Company Announcements
AN2 Therapeutics’ High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties
7M ago
ANTX
AN2 Therapeutics reports Q4 EPS (57c), consensus (75c)
PremiumThe Fly
AN2 Therapeutics reports Q4 EPS (57c), consensus (75c)
8M ago
ANTX
ANTX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ANTX Earnings this Week: How Will it Perform?
8M ago
ANTX
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
PremiumThe Fly
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
8M ago
ANTX
INSM
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
PremiumThe Fly
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
8M ago
ANTX
INSM
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
PremiumThe FlyCantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
8M ago
ANTX
INSM
SHAREHOLDER ALERT: Potential Recovery for AN2 Therapeutics, Inc. (ANTX) Investors
Premium
Class Action
SHAREHOLDER ALERT: Potential Recovery for AN2 Therapeutics, Inc. (ANTX) Investors
9M ago
ANTX
AN2 Therapeutics Inc trading resumes
Premium
The Fly
AN2 Therapeutics Inc trading resumes
9M ago
ANTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >